Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Escalation, group and A + B designs for dose-finding trials.

Literature DB >> 16381057

Escalation, group and A + B designs for dose-finding trials.

Abstract

In this paper, rules are given on how to construct escalation, A + B, and group designs for dose-finding trials. Operational characteristics of these designs are discussed and compared via simulations. Dose-finding designs for trials with ordinal toxicity outcome are considered.

Entities: Disease

Mesh：

Substances：

Year: 2006 PMID： 16381057 DOI： 10.1002/sim.2470

Source DB: PubMed Journal: Stat Med ISSN： 0277-6715 Impact factor: 2.373

Keyword Cloud
Cited

15 in total

1. Incorporating lower grade toxicity information into dose finding designs.

Authors: Alexia Iasonos; Sarah Zohar; John O'Quigley
Journal: Clin Trials Date: 2011-08 Impact factor: 2.486

2. Quality assessment of phase I dose-finding cancer trials: proposal of a checklist.

Authors: Sarah Zohar; Qing Lian; Vincent Levy; Ken Cheung; Anastasia Ivanova; Sylvie Chevret
Journal: Clin Trials Date: 2008 Impact factor: 2.486

3. Dose finding for continuous and ordinal outcomes with a monotone objective function: a unified approach.

Authors: Anastasia Ivanova; Se Hee Kim
Journal: Biometrics Date: 2008-05-13 Impact factor: 2.571

4. The superiority of the time-to-event continual reassessment method to the rolling six design in pediatric oncology Phase I trials.

Authors: Lili Zhao; Julia Lee; Rajen Mody; Thomas M Braun
Journal: Clin Trials Date: 2011-05-24 Impact factor: 2.486

5. A likelihood-based approach for computing the operating characteristics of the 3+3 phase I clinical trial design with extensions to other A+B designs.

Authors: Cody Chiuzan; Elizabeth Garrett-Mayer; Sharon D Yeatts
Journal: Clin Trials Date: 2014-10-27 Impact factor: 2.486

Escalation, group and A + B designs for dose-finding trials.

1. Incorporating lower grade toxicity information into dose finding designs.

2. Quality assessment of phase I dose-finding cancer trials: proposal of a checklist.

3. Dose finding for continuous and ordinal outcomes with a monotone objective function: a unified approach.

4. The superiority of the time-to-event continual reassessment method to the rolling six design in pediatric oncology Phase I trials.

5. A likelihood-based approach for computing the operating characteristics of the 3+3 phase I clinical trial design with extensions to other A+B designs.

6. Advances in Statistical Approaches Oncology Drug Development.

7. Dose-finding designs for trials of molecularly targeted agents and immunotherapies.

8. Comparison of Isotonic Designs for Dose-Finding.

9. Sample size formulae for the Bayesian continual reassessment method.

10. Dose finding when the target dose is on a plateau of a dose-response curve: comparison of fully sequential designs.